VC Julie Grant argues U.S. should not restrict biotech investments in China

Julie Grant, a venture capitalist, told STAT+ that she opposes any U.S. effort to limit biotech investments in China.

She says the biotech sector has become increasingly interdependent over decades, with U.S. companies relying on Chinese research and vice-versa, and that cutting off that flow would be short-sighted.

Some lawmakers are trying to add biotechnology to the COINS Act, which would let the government review licensing deals, equity investments and other collaborations with Chinese firms. Grant argues such restrictions would hinder growth and are not feasible.